The strength of female sex as a prognostic factor in XXXX : a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit.

@entity1 @entity137 @entity33 @entity281 @entity151 @entity204
BACKGROUND: Previous studies reported that @entity1 survive longer than @entity1 , but experience greater @entity137 , when treated for @entity151 ( @entity151 ). METHODS: Individual @entity1 data from six randomized phase II/III chemotherapy trials, from the Manchester Lung Group and UK Medical Research Council, were pooled for analysis. End points included overall survival, response rate, @entity137 , dose intensity (DI) and transfusion rates. RESULTS: Of 1707 @entity1 analyzed, 44% were @entity1 . At baseline, @entity1 had poorer performance status (PS) (57% versus 67% Eastern Cooperative Oncology Group PS 0-1/Karnofsky PS 80-100, P = 0.0004) and more were of normal weight or underweight (57% versus 48%, P = 0.003), but fewer were anemic (25% versus 62%, P < 0.0001). Response rates between @entity1 and @entity1 were similar (77% versus 76%, P = 0.64). In univariate [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.76-0.96, P = 0.006] and multivariate (HR 0.88, 95% CI 0.79-0.99, P = 0.04) analyses, female sex predicted for longer survival. @entity1 experienced more grade 3/4 emesis (18% versus 9%, P < 0.0001) and grade 3/4 @entity33 (13% versus 8%, P = 0.005) than @entity1 . There were no differences in DI, @entity281 , transfusions or treatment-related @entity204 . CONCLUSION: Data from >1700 @entity1 in randomized @entity151 chemotherapy trials confirm that @entity1 survive modestly longer than @entity1 but may experience greater @entity137 .
